Detection of RB1 deletions by fluorescence in situ hybridization in malignant hematologic disorders

Amy L. Juneau, Marian Kaehler, Eric R. Christensen, Chris R. Schad, Alan R. Zinsmeister, John Lust, Curtis Hanson, Gordon W. Dewald

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

We evaluated the usefulness of fluorescence in situ hybridization (FISH) using different-colored commercial RB1 and 13qter DNA probes to identify RB1 deletions in interphase nuclei of bone marrow from 24 patients with agnogenic myeloid metaplasia (AMM), 20 patients with multiple myeloma (MM), 21 patients with other hematologic malignancies, and 25 normal bone marrow transplant (BMT) donors. Based on the 25 normal BMT donors, the upper boundary for the normal percentage of nuclei with one RB1 signal was 6.5%. Based on eight specimens known to have a deletion of 13q14 by cytogenetic studies, the lower limit of abnormal for the percentage of nuclei with one RB1 signal was 12.5%. More than 12.5% of nuclei had a single RB1 signal in 7/24 (29%) patients with AMM and 3/20 (15%) patients with MM. None of the 21 patients with hematologic malignancies other than AMM or MM had more than 12.5% nuclei with loss of RB1. The results of t his study suggest that FISH with RB1 probes is useful to detect loss of RB1 in interphase nuclei from patients with hematologic disorders who have chromosome abnormalities involving 13q14. Thus, FISH with probes for RB1 is efficacious to investigate the pathogenesis of RB1 in malignant neoplasms and is a useful adjunct to conventional cytogenetic studies in clinical practice when abnormalities of 13q14 are involved.

Original languageEnglish (US)
Pages (from-to)117-123
Number of pages7
JournalCancer Genetics and Cytogenetics
Volume103
Issue number2
DOIs
StatePublished - 1998

Fingerprint

Fluorescence In Situ Hybridization
Primary Myelofibrosis
Multiple Myeloma
Bone Marrow
Interphase
Hematologic Neoplasms
Cytogenetics
Tissue Donors
DNA Probes
Chromosome Aberrations
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Genetics
  • Molecular Biology

Cite this

Juneau, A. L., Kaehler, M., Christensen, E. R., Schad, C. R., Zinsmeister, A. R., Lust, J., ... Dewald, G. W. (1998). Detection of RB1 deletions by fluorescence in situ hybridization in malignant hematologic disorders. Cancer Genetics and Cytogenetics, 103(2), 117-123. https://doi.org/10.1016/S0165-4608(97)00408-1

Detection of RB1 deletions by fluorescence in situ hybridization in malignant hematologic disorders. / Juneau, Amy L.; Kaehler, Marian; Christensen, Eric R.; Schad, Chris R.; Zinsmeister, Alan R.; Lust, John; Hanson, Curtis; Dewald, Gordon W.

In: Cancer Genetics and Cytogenetics, Vol. 103, No. 2, 1998, p. 117-123.

Research output: Contribution to journalArticle

Juneau, AL, Kaehler, M, Christensen, ER, Schad, CR, Zinsmeister, AR, Lust, J, Hanson, C & Dewald, GW 1998, 'Detection of RB1 deletions by fluorescence in situ hybridization in malignant hematologic disorders', Cancer Genetics and Cytogenetics, vol. 103, no. 2, pp. 117-123. https://doi.org/10.1016/S0165-4608(97)00408-1
Juneau, Amy L. ; Kaehler, Marian ; Christensen, Eric R. ; Schad, Chris R. ; Zinsmeister, Alan R. ; Lust, John ; Hanson, Curtis ; Dewald, Gordon W. / Detection of RB1 deletions by fluorescence in situ hybridization in malignant hematologic disorders. In: Cancer Genetics and Cytogenetics. 1998 ; Vol. 103, No. 2. pp. 117-123.
@article{0955e6e781ca4eff83981a1e4c0f9ac7,
title = "Detection of RB1 deletions by fluorescence in situ hybridization in malignant hematologic disorders",
abstract = "We evaluated the usefulness of fluorescence in situ hybridization (FISH) using different-colored commercial RB1 and 13qter DNA probes to identify RB1 deletions in interphase nuclei of bone marrow from 24 patients with agnogenic myeloid metaplasia (AMM), 20 patients with multiple myeloma (MM), 21 patients with other hematologic malignancies, and 25 normal bone marrow transplant (BMT) donors. Based on the 25 normal BMT donors, the upper boundary for the normal percentage of nuclei with one RB1 signal was 6.5{\%}. Based on eight specimens known to have a deletion of 13q14 by cytogenetic studies, the lower limit of abnormal for the percentage of nuclei with one RB1 signal was 12.5{\%}. More than 12.5{\%} of nuclei had a single RB1 signal in 7/24 (29{\%}) patients with AMM and 3/20 (15{\%}) patients with MM. None of the 21 patients with hematologic malignancies other than AMM or MM had more than 12.5{\%} nuclei with loss of RB1. The results of t his study suggest that FISH with RB1 probes is useful to detect loss of RB1 in interphase nuclei from patients with hematologic disorders who have chromosome abnormalities involving 13q14. Thus, FISH with probes for RB1 is efficacious to investigate the pathogenesis of RB1 in malignant neoplasms and is a useful adjunct to conventional cytogenetic studies in clinical practice when abnormalities of 13q14 are involved.",
author = "Juneau, {Amy L.} and Marian Kaehler and Christensen, {Eric R.} and Schad, {Chris R.} and Zinsmeister, {Alan R.} and John Lust and Curtis Hanson and Dewald, {Gordon W.}",
year = "1998",
doi = "10.1016/S0165-4608(97)00408-1",
language = "English (US)",
volume = "103",
pages = "117--123",
journal = "Cancer Genetics and Cytogenetics",
issn = "0165-4608",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Detection of RB1 deletions by fluorescence in situ hybridization in malignant hematologic disorders

AU - Juneau, Amy L.

AU - Kaehler, Marian

AU - Christensen, Eric R.

AU - Schad, Chris R.

AU - Zinsmeister, Alan R.

AU - Lust, John

AU - Hanson, Curtis

AU - Dewald, Gordon W.

PY - 1998

Y1 - 1998

N2 - We evaluated the usefulness of fluorescence in situ hybridization (FISH) using different-colored commercial RB1 and 13qter DNA probes to identify RB1 deletions in interphase nuclei of bone marrow from 24 patients with agnogenic myeloid metaplasia (AMM), 20 patients with multiple myeloma (MM), 21 patients with other hematologic malignancies, and 25 normal bone marrow transplant (BMT) donors. Based on the 25 normal BMT donors, the upper boundary for the normal percentage of nuclei with one RB1 signal was 6.5%. Based on eight specimens known to have a deletion of 13q14 by cytogenetic studies, the lower limit of abnormal for the percentage of nuclei with one RB1 signal was 12.5%. More than 12.5% of nuclei had a single RB1 signal in 7/24 (29%) patients with AMM and 3/20 (15%) patients with MM. None of the 21 patients with hematologic malignancies other than AMM or MM had more than 12.5% nuclei with loss of RB1. The results of t his study suggest that FISH with RB1 probes is useful to detect loss of RB1 in interphase nuclei from patients with hematologic disorders who have chromosome abnormalities involving 13q14. Thus, FISH with probes for RB1 is efficacious to investigate the pathogenesis of RB1 in malignant neoplasms and is a useful adjunct to conventional cytogenetic studies in clinical practice when abnormalities of 13q14 are involved.

AB - We evaluated the usefulness of fluorescence in situ hybridization (FISH) using different-colored commercial RB1 and 13qter DNA probes to identify RB1 deletions in interphase nuclei of bone marrow from 24 patients with agnogenic myeloid metaplasia (AMM), 20 patients with multiple myeloma (MM), 21 patients with other hematologic malignancies, and 25 normal bone marrow transplant (BMT) donors. Based on the 25 normal BMT donors, the upper boundary for the normal percentage of nuclei with one RB1 signal was 6.5%. Based on eight specimens known to have a deletion of 13q14 by cytogenetic studies, the lower limit of abnormal for the percentage of nuclei with one RB1 signal was 12.5%. More than 12.5% of nuclei had a single RB1 signal in 7/24 (29%) patients with AMM and 3/20 (15%) patients with MM. None of the 21 patients with hematologic malignancies other than AMM or MM had more than 12.5% nuclei with loss of RB1. The results of t his study suggest that FISH with RB1 probes is useful to detect loss of RB1 in interphase nuclei from patients with hematologic disorders who have chromosome abnormalities involving 13q14. Thus, FISH with probes for RB1 is efficacious to investigate the pathogenesis of RB1 in malignant neoplasms and is a useful adjunct to conventional cytogenetic studies in clinical practice when abnormalities of 13q14 are involved.

UR - http://www.scopus.com/inward/record.url?scp=0032103266&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032103266&partnerID=8YFLogxK

U2 - 10.1016/S0165-4608(97)00408-1

DO - 10.1016/S0165-4608(97)00408-1

M3 - Article

C2 - 9614909

AN - SCOPUS:0032103266

VL - 103

SP - 117

EP - 123

JO - Cancer Genetics and Cytogenetics

JF - Cancer Genetics and Cytogenetics

SN - 0165-4608

IS - 2

ER -